Magnetic resonance (MR) imaging as a marker for multiple sclerosis.

Area of Science:

• Neurology
• Radiology
• Clinical Trials

Background:

• Multiple sclerosis (MS) diagnosis can be challenging, necessitating objective measures.
• New MS therapies require reliable outcome parameters for short-term trials.
• Magnetic resonance imaging (MRI) is crucial for both MS diagnosis and disease progression monitoring.

Purpose of the Study:

• To highlight the role of MRI in diagnosing MS.
• To emphasize MRI's utility as an outcome measure in clinical trials for assessing new MS therapies.
• To discuss the importance of MRI in monitoring disease progression and treatment response.

Main Methods:

• Utilizing serial MRI scans to detect active lesions with gadolinium enhancement in exploratory trials.
• Employing MRI as a primary outcome measure in early-phase trials to assess drug efficacy.
• Using yearly MRI scans to monitor disease progression via changes in total lesion load.

Main Results:

• MRI can detect disease activity by quantifying gadolinium-enhancing lesions.
• Phase II trials demonstrate MRI's capability to show treatment effects on lesion development, even in small patient groups.
• Serial MRI scans are valuable for tracking overall disease progression, indicated by increased lesion load.

Conclusions:

• MRI is an indispensable tool for diagnosing MS and monitoring its progression.
• MRI serves as a valuable outcome measure in clinical trials, particularly in early phases, for evaluating new MS therapies.
• Optimizing spatial resolution in serial MRI scans is essential for reproducible lesion assessment and monitoring treatment efficacy.